Target intelligence / Profile preview

Phosphoinositide 3-kinase (PI3K)

Target
PI3K
Molecular classification
Enzyme, Lipid kinase, Signal transduction molecule, Intracellular signaling enzyme
01

Overview

Phosphoinositide 3-kinase (PI3K) refers to a family of intracellular lipid kinases that phosphorylate the 3-position hydroxyl group of the inositol ring of phosphoinositides. The most common substrate is phosphatidylinositol-4,5-bisphosphate (PIP2), yielding phosphatidylinositol-3,4,5-trisphosphate (PIP3). PI3Ks are divided into three classes (I, II, III) based on structure and substrate specificity; class I is the best described and most relevant to human disease, with four isoforms (p110α, β, γ, δ). PI3K signaling is crucial for controlling cell survival, growth, proliferation, metabolism, and motility, and it plays a major role in immune cell function. Dysregulation of PI3K, often through genetic mutation or overactivation, contributes to oncogenesis and is a common driver in several cancers; the pathway is also implicated in inflammation and immune disorders. Several PI3K inhibitors are approved or in development for cancer and immune diseases, but on-target toxicities present therapeutic challenges.

Other names
Phosphatidylinositol 3-kinasePhosphoinositide 3-kinasePI3KPI 3-kinasePhosphatidylinositol-4,5-bisphosphate 3-kinase
02

Mechanism of action

Inhibition of the kinase activity, blocking phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), which reduces activation of the downstream AKT/mTOR pathway Immunomodulation (e.g., modulation of B cell or T cell signaling in inflammatory/autoimmune diseases)

03

Biological functions

Signal transductionCell growthCell proliferationSurvivalMotilityDifferentiationIntracellular traffickingImmune response
04

Disease associations

CancerInflammationAutoimmunityImmunodeficiencyOther (implicated in cardiovascular and metabolic diseases)
05

Safety considerations

HyperglycemiaRashGastrointestinal toxicity (colitis, diarrhea)PneumonitisImmune-related adverse effectsOpportunistic infections (especially with PI3K-delta inhibitors)
06

Interacting drugs

Idelalisib

5 more in the full profile.

07

Biomarkers

PIK3CA activating mutations (for certain PI3K-alpha inhibitors in cancer)PTEN loss or mutationAKT phosphorylation levelsPI3K pathway activation status (by gene/protein assay)

Beyond the preview

Go deeper on Phosphoinositide 3-kinase (PI3K).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphoinositide 3-kinase (PI3K).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call